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Summary
Background: Despite the high prevalence rates of HIV infection in women, epidemiological
studies conducted exclusively on HIV-reactive women are very sparse, particularly from the
state of Andhra Pradesh, India, where the overall prevalence rate among antenatal women is
2.1%.
Study population: Medical records of 2643 HIV-reactive women, identified during a 12-year
period, were reviewed for epidemiological and clinical information about HIV in women.
Results: The overall prevalence of HIV-reactive women was 1.6% and trends were in parallel with
those observed by the HIV sentinel surveillance study from our state. Overall 24.5% of HIV-
infected cases were women, ranging from 6.3% in 1993 to 28.9% in 2004. HIV infection was
increasingly found in women over 30 years of age. Heterosexual contact (87.3%) was the most
common route of HIV transmission. The majority (75.2%) of the women were asymptomatic.
Women, compared to men, suffered more from respiratory and bacterial infections, often
pneumonia, and from gender-specific manifestations like vaginal candidal infections. Following
the introduction of antiretroviral (ARV) therapy in our hospital in 1999, only 8.5% of HIV-reactive
women have received ARV treatment.
Conclusion: There is a need for gender- andage-specificHIV surveillance amongwomen, especially
from areas of high prevalence. Our study shows that there are good reasons to be concerned about
the effects of HIV in women. We stress the importance of increasing the focus of attention on the
impact of this pandemic on women as we enter the 25th year since its emergence.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
‘‘Women, Girls, HIV and AIDS’’ was the theme of the 2004
World AIDS day. A decade ago women seemed to be on the* Corresponding author. Tel.: +91 40 23736173;
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doi:10.1016/j.ijid.2005.09.006periphery of the AIDS epidemic. Today they are of central
concern and are one of the fastest growing groups of new AIDS
cases, accounting for close to half of the 37.2 million adults
living with HIV worldwide in 20041; one woman is infected
with HIV every 20 seconds throughout the world.2 In India,
where nearly 40% of HIV-infected cases are women,3 they are
quickly becoming the new face of AIDS. This region of the
world is hardest hit by the disease and may herald the future
of AIDS worldwide. In the current context of poverty, lowerPublished by Elsevier Ltd. All rights reserved.
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women and girls of 15 to 24 years of age are at a higher risk of
HIV infection than young men and boys.
Though many studies have been done on women either
with high-risk behavior or in pregnancy,4—6 epidemiological
studies or large-scale hospital-based studies conducted
exclusively on women for HIV prevalence are very few.7—17
The same is true in India, where such studies are very
sparse,18—20 particularly from the state of Andhra Pradesh,
where the overall prevalence rate among antenatal women is
about 2.1% (0.8—4%).3 Such studies are essential in order to
understand the trend of the infection.
This retrospective study was undertaken at Nizam’s Insti-
tute of Medical Sciences with the aim of obtaining clinical
information on women with HIV, the changing trends of HIV
infection in various age groups and different occupations,
and the differences in clinical manifestations in HIV-reactive
women compared to men. A comparison was also made
between the sentinel surveillance data of antenatal women
and our hospital-based data of HIV-infected women.
Study population and methods
A retrospective study was conducted covering the 12-year
period from 1993 to 2004, on a total of 10 797 HIV-reactive
patients identified at Nizam’s Institute of Medical Sciences, a
tertiary care hospital and university in Hyderabad, South
India.
Data from all HIV-reactive patients have been maintained
at our institute since 1993. These data have been obtained by
a structured interview for both outpatient and inpatient
cases, and additionally by reviewing the medical records
of inpatients (as in the case of 11.6% of women in our study).
To avoid any bias, only two people (authors) collected the
study data. Anonymity and confidentiality were maintained
and ethical clearance was obtained from the institute’s
ethical committee. There is no dedicated retroviral diseasesFigure 1 Comparison of the prevalence of HIV-reactive women fro
surveillance study (1998—2004). NIMS, Nizam’s Institute of Medical(RVD) ward in our hospital and these data represent HIV-
reactive cases from all the units of the Institute.
All serum samples were evaluated by enzyme-linked
immunoassay for HIV antibodies: from 1993 to 1996 by using
a 2nd generation assay, from 1996 to April 2003 by using 3rd
generation ELISA kits, and from then onwards using 4th
generation kits (Vironostika HIV Ag/Ab from BioMerieux).
With the improvement in the sensitivity of diagnostic kits
with each new generation, the detection of HIV-reactive
cases has become more accurate in recent years. The
WHO/UNAIDS strategy III for the diagnosis of the disease in
patients has been followed since 1995 in order to decisively
establish the presence of HIV infection. CD4 testing in our
institute was commenced in August 1999 using the FACS
Count (Becton & Dickinson) system, courtesy of the National
AIDS Control Organization (NACO), Government of India.
Of the 2643 HIV-reactive women, available data from 2035
women were reviewed for demographic information including
age,marital status,HIV status of the spouse, andoccupationof
self and that of the spouse. Data from 608 women with HIV
infection were not available. Information concerning route of
transmission,useofHIVtherapy, andotherclinical information
were collected. For the comparison of systemic and opportu-
nistic infections in HIV-reactive women with those of reactive
men, data from 5817 HIV-reactive men were reviewed. Data
were analyzed using Epi-info version 5, CDC and estimates of
all the key variables and the indicators were calculated. Based
on clinical signs and symptoms, the women with HIV infection
were categorized into the four stages defined by the World
HealthOrganization (WHO), and based on their CD4 cell counts
they were categorized as per the Centers for Disease Control
and Prevention (CDC) criteria.
Results
Of the 10 797 HIV-reactive cases at our institute, 2643 (24.5%)
were women. There has been a considerable rise in the
proportion of women among HIV reactives (Figures 1 andm this study with the prevalence found by the State HIV sentinel
Sciences.
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Figure 2 Yearly proportion of HIV-reactive women by age group (total reactive women = 2643).2). The clinical symptoms and various systemic and oppor-
tunistic infections noted during different stages of HIV infec-
tion are shown in Figure 3. Of the infected women, 86% were
housewives. Due to financial constraints CD4 testing was not
performed on all HIV-reactive women. A total of 1985 women
were screened for CD4 cell counts from 1999 onwards (the
year when CD4 testing was started at our institute). DataFigure 3 Opportunistic and other associated infections with c
(women = 2035, men = 5817).from 1514 females were available and analyzed as per the
CDC classification using the CD4 counts (Table 1). All these
women were categorized into the four WHO stages of the
disease based on their clinical history.
Of the HIV-reactive women, 307/2643 (11.6%) were
admitted to our institute with various HIV or non-HIV related
complications. Of these, 24.8% had required emergencylinical symptoms in HIV-reactive individuals from the study
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Table 1 Symptomatic classification of 1514 HIV-reactive women as per the CDC guidelines using CD4 counts and the WHO clinical
staging system
CD4 cell counts Clinical categories Total
1 Asymptomatic 2 Mild disease 3 Moderate disease 4 Severe disease
A >500 cells/mL A1 = 738 A2 = 6 A3 = 4 A4 = 1 749 (49.5%)
B 200—499 cells/mL B1 = 342 B2 = 10 B3 = 65 B4 = 17 434 (28.7%)
C <200 cells/mL C1 = 58 C2 = 29 C3 = 41 C4 = 203 331 (21.9%)
Total 1138 (75.2%) 45 110 221 1514services and 76.3% of these emergency cases were admitted
due to HIV-related complications, commonly with unex-
plained fever, diarrhea,Mycobacterium tuberculosis, or with
other opportunistic infections. A mortality rate of 13.4% (41/
307) was recorded among the hospitalized HIV-infected
women. The most common identifiable cause resulting in
death was an acute illness with multi-organ failure. Since the
introduction of highly active antiretroviral therapy (HAART)
at our institute in 1999, 2054 women have been found to be
HIV-reactive, and even though 23.8% of them were sympto-
matic, only 8.5% of them had received therapy.
Discussion
A woman’s biologic, cultural, economic, and social status can
affect her likelihood of becoming infected with HIV.11 Accord-
ing to theUNAIDS estimate,womennowmake up nearly half of
the 37.2 million adults aged between 15 and 49 living with HIV
worldwide. This percentage has risen dramatically over the
past 24 years since the AIDS epidemic was first detected.
Today, women are probably one of the most vulnerable risk
groups for HIV infection. In the Indian context, the epidemic in
women is spreading at a prolific rate, which can be observed
from the sharp increase in the yearly proportion of HIV-
infected women.3 This is due to a large population of one
billion, large numbers of commercial sexworkers,mobilemale
workers, and a high prevalence of sexually transmitted dis-
eases (STDs). Based on cases reported to NACO, by the end of
January 2005 a total of 70 075 men and 27 705 women in India
were reported as having AIDS.3
Even though our hospital does not have a gynecology unit,
all the other units are represented, and the HIV prevalence
rates were similar to those seen in the state HIV sentinel
surveillance results (Figure 1). 24.5% of HIV-infected cases at
our institute were women. A fluctuating prevalence was
observed that ranged between 6.3% in 1993 and 28.9% in
2004 (Figure 2). The decreased prevalence rates in the years
1999, 2001, 2002, and 2003 as seen from both our data and
those of the state surveillance, could be due to the successful
implementation of antiretroviral therapy (ARV) as well as the
HIV prevention programs. But in 2004 the prevalence again
increased, suggesting the possible establishment of drug-
resistant mutants as well as of more virulent and transmis-
sible HIV subtypes in this part of India.
In many developing countries, about 50—60% of all new
HIV infections occur in the 15—24 years age group. However,
unlike the population-based data, our hospital-based data
showed a higher prevalence among the older age groups,
when clinical symptoms start to set in and the infectionbegins to manifest itself. Of the HIV-infected women,
22.8% presented to the hospital with an HIV/AIDS-related
illness. HIV in older women, who are at greater risk, is
difficult to detect, and a possible infection will be missed
unless routine testing alongside their spouse occurs.
Heterosexual behavior was determined to be the main
route of transmission of HIV in our study, and was seen in
87.3% of our cases. Women are more likely to become
infected than are men due to a substantial mucosal exposure
to seminal fluids. Studies show that male-to-female trans-
mission of HIV appears to be twice as efficient as female-to-
male transmission. Our study also shows that men, especially
spouses, have been the most common route of HIV transmis-
sion to women. Marriage provides no protection to women
against HIV. It was observed from the interview that extra-
marital relations among women were still uncommon even
though that percentage has been seen to increase from 0.6%
in 1999 to 8.6% in 2004. In fact, the primary risk factor for HIV
in married women appears to be whether their spouses are
engaged in extramarital or commercial sex. Many of the
married women admitted to not using any barrier during
sex as they had faith in their husbands, similar findings to
those of a study in Brazil.21,22 Transmission of the infection by
blood transfusion has seen a gradual reduction over the
years, from 33.3% in 1993 to 4.1% in 2004, due to the
successful implementation of donor screening in blood banks.
Only 22.8% of women were symptomatic, and fatigue,
prolonged fever, cough, and oral ulcers were some of the
common clinical features observed (Figure 3). Interestingly,
physicians only suspected HIV infection in 11.4% (231/2035)
of cases, showing how frequently they fail to recognize the
early symptoms of HIV in women.
Of the common systemic infections found in HIV-infected
women, TB and candidiasis were the most common oppor-
tunistic infections, followed by bacterial and genital fungal
infections (Figure 3). The diagnoses of all these bacterial,
viral, and fungal infections were based on the recommended
radiological, serological, pathological, biochemical, and cul-
ture test results. Even though women suffer from the same
clinical manifestations of HIV infection as men, our study has
shown that women have more bacterial infections, respira-
tory infections (often pneumonia), and gender-specific man-
ifestations such as recurrent vaginal candidal infections,
severe pelvic inflammatory disease, herpes simplex infec-
tions, etc.23,24 The CDC currently recommends that every
HIV-positive woman should have a complete gynecologic
evaluation as part of her initial HIV evaluations.
As many Indian women are still less likely than men to be
diagnosed early and to receive early treatment, 13.4% (41/
307) of the admitted females could not survive the infection,
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sion to AIDS and death than men at similar CD4 cell
counts.25,26 All the clinical data from the 1514 HIV-reactive
women, when categorized as per theWHO clinical HIV staging
system, showed that most of the women (75.2%) were asymp-
tomatic and had got their HIV test done on the recommenda-
tion of the physician due to the reactive status of the spouse.
With the CD4 counts of these 1514 women categorized as per
the CDC classification, 49.5% had CD4 counts of >500 cells/
mL whereas 21.9% had <200 cells/mL (Table 1). Even though
24.8% of the women (376/1514) were symptomatic, only
27.4% of these symptomatic women (103/376) were on
ARV treatment mainly due to lack of access and information.
However, only 41% of those on ARV treatment had good levels
of adherence and this may have affected their ability to deal
with opportunistic infections, results similar to those of a
study carried out in Pennsylvania.27 Women probably also
reported late to the hospital and so could not receive ade-
quate treatment at an appropriate time. Many women did not
know much about the available health services and treat-
ments, and further, due to complex economic and social
reasons, fewer women had access to early AIDS care. The
reasons for nonadherence to therapy were mostly poverty,
ignorance, and adverse effects of drugs, similar to other
studies that have shown that women are more likely than
men to experience several ARV-associated adverse
effects.13,27,28
Of the women included in the study, 86% were housewives.
By occupation, their HIV-infected spouses were almost uni-
formly distributed across the various occupational cate-
gories. This again emphasizes the fact that, from what was
once thought of as a problem of high-risk groups like com-
mercial sex workers and migrant workers, the virus has
entered the communities of businessmen, laborers, students,
etc. (i.e., the general population), and is affecting the
vulnerable housewife, who up until more recently was in
the low-risk group.
The study reported here has confronted several limita-
tions. Firstly, due to the unwillingness of the respondents,
data from all the women could not be obtained. Secondly, the
asking of questions concerning sexual beliefs and behaviors
was restricted, and because of the nature of the question-
naire, the honesty of the individuals’ responses may be called
into question.
Conclusion
Although HIV/AIDS affects both men and women, with the
rapid increase in the rate of HIV cases in women, research in
this area is particularly important. In India, women appear to
be the most vulnerable group in the community for HIV
infection. On many occasions doctors and healthcare provi-
ders have failed to recognize the early symptoms of HIV in
women and should be alert to any abnormal clinical mani-
festations in them. Early diagnosis of HIV infection allows
women to have early monitoring of CD4 counts and if needed
to take full advantage of antiretroviral treatments and pre-
ventive medicines for opportunistic infections.
Our study has shown that there is good cause to be
concerned about for the effects of HIV in women and
stresses the importance of focusing targeted interventionson women in areas of high prevalence as we enter into the
25th year of the HIV pandemic. These data underscore the
importance of more research on women and AIDS in settings
where heterosexual contact is an important mode of HIV
transmission.
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